These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 38786075)

  • 41. Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.
    Derman BA; Zha Y; Zimmerman TM; Malloy R; Jakubowiak A; Bishop MR; Kline J
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
    Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
    BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
    Kaiser MF; Hall A; Walker K; Sherborne A; De Tute RM; Newnham N; Roberts S; Ingleson E; Bowles K; Garg M; Lokare A; Messiou C; Houlston RS; Jackson G; Cook G; Pratt G; Owen RG; Drayson MT; Brown SR; Jenner MW
    J Clin Oncol; 2023 Aug; 41(23):3945-3955. PubMed ID: 37315268
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.
    Straka C; Salwender H; Knop S; Vogel M; Müller J; Metzner B; Langer C; Sayer H; Jung W; Dürk HA; Bassermann F; Gramatzki M; Rösler W; Wolf HH; Brugger W; Engelhardt M; Fischer T; Liebisch P; Einsele H
    Eur J Haematol; 2021 Nov; 107(5):529-542. PubMed ID: 34270825
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On
    Cho HJ; Baek DW; Kim JH; Lee J; Chung YK; Jung SH; Song GY; Ahn SY; Ahn JS; Yang DH; Lee JJ; Kim HJ; Hong CM; Jeong SY; Min JJ; Sohn SK; Moon JH
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):113-120. PubMed ID: 34598908
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.
    Lahoud OB; Landau H; Nguyen J; Devlin S; Lendvai N; Weltz J; Ayorinde T; Chung DJ; Lesokhin AM; Kewalramani T; Korde N; Mailankody S; Landgren O; Giralt S; Comenzo RL; Hassoun H
    Leuk Lymphoma; 2022 Sep; 63(9):2126-2135. PubMed ID: 35648041
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma.
    Abdallah AO; Mohyuddin GR; Mahmoudjafari Z; Atrash S; Kawsar H; Sigle M; Shune L; McGuirk J; Ganguly S
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e212-e219. PubMed ID: 33051166
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
    Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
    Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy.
    Lee BH; Shin SH; Min CK; Yhim HY; Kwak JY; Kim JA
    Int J Hematol; 2013 May; 97(5):634-9. PubMed ID: 23605366
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
    Tacchetti P; Talarico M; Barbato S; Pantani L; Mancuso K; Rizzello I; Zamagni E; Cavo M
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):379-395. PubMed ID: 38798125
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?
    Richardson PG; Laubach JP; Munshi NC; Anderson KC
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):255-61. PubMed ID: 25696864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current status of autologous stem cell transplantation for multiple myeloma.
    Al Hamed R; Bazarbachi AH; Malard F; Harousseau JL; Mohty M
    Blood Cancer J; 2019 Apr; 9(4):44. PubMed ID: 30962422
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
    Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
    Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is there still a role for stem cell transplantation in multiple myeloma?
    Mina R; Lonial S
    Cancer; 2019 Aug; 125(15):2534-2543. PubMed ID: 30985927
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.
    Dimopoulos MA; Jakubowiak AJ; McCarthy PL; Orlowski RZ; Attal M; Bladé J; Goldschmidt H; Weisel KC; Ramasamy K; Zweegman S; Spencer A; Huang JSY; Lu J; Sunami K; Iida S; Chng WJ; Holstein SA; Rocci A; Skacel T; Labotka R; Palumbo A; Anderson KC
    Blood Cancer J; 2020 Feb; 10(2):17. PubMed ID: 32054831
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
    Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Béné MC; Zweegman S; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Stoppa AM; van de Donk NWCJ; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Krevvata M; Zhang K; de Boer C; Vara S; Kampfenkel T; Vanquickelberghe V; Vermeulen J; Avet-Loiseau H; Sonneveld P
    Lancet Oncol; 2021 Oct; 22(10):1378-1390. PubMed ID: 34529931
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
    Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
    Front Oncol; 2020; 10():624661. PubMed ID: 33680948
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
    Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
    Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017.
    Terpos E;
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):321-334. PubMed ID: 29576386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.